Protect your patients from recurrent stroke
After a PFO-associated stroke, you can significantly reduce your patient's risk of stroke recurrence by referring them for PFO closure.
Learn about the procedure
Reducing Risk of Recurrent Stroke Close The Patent Foramen Ovale (PFO)
About one quarter of ischemic strokes are of unknown cause¹
Nearly half of patients with an ischemic stroke of unknown cause have a PFO²
Patients experience a 59% risk reduction of a recurrent stroke after PFO closure³
Find out how PFO closure might help your patients
The Amplatzer™ Talisman™ PFO Occluder is built off a legacy of excellence, with over 20 years as the market-leading and most-studied PFO device.
Treatment options
Reduce risk of stroke recurrence
The Amplatzer PFO Occluder was studied in the RESPECT Trial in the US and Canada. The trial enrolled 980 patients, between the ages of 18 to 60, who were diagnosed with a PFO and a cryptogenic stroke. Patients were randomly assigned to receive either the Amplatzer PFO Occluder plus blood-thinning medication, or blood-thinning medication alone.
The RESPECT Trial was designed to evaluate whether PFO closure with the Amplatzer PFO Occluder plus blood-thinning medication was more effective in reducing the risk of another ischemic stroke compared with the sole use of blood-thinning medication. Over a median follow-up period of 5.9 years, the rate of recurrent ischemic stroke was 45% lower with PFO closure compared to medical management exclusively.⁴
In 2020, the American Academy of Neurology (AAN) performed a meta-analysis of 8 randomized controlled trials on PFO closure. The AAN concluded that compared to antiplatelet medication alone, PFO closure plus antiplatelet medication resulted in a 59% risk reduction of recurrent stroke.³
About the Amplatzer Talisman PFO OccluderNeurologist recommended
With that collaborative spirit [between neurologists and cardiologists]...device placement can occur quite safely and can be HIGHLY effective in reducing stroke with benefits of 50-97% relative reduction in stroke rates.”
The turning point for PFO Closure
Clinical studies have confirmed the superiority of PFO closure to medical management in reducing the risk of stroke recurrence.³
View the dataMultiple physician societies now recommend PFO closure in select patients.
Read the Guidelines- Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377:1022-32. doi: 10.1056/NEJMoa1610057
- Mojadidi, MK, Zaman MO, Elgendy IY, et al Cryptogenic stroke and patent foramen foramen ovale. J Amer Coll Cardiol. 2018;71:1035-43. doi: 10.1016/j.jacc.2017.12.059
- Messé SR, Gronseth GS, Kent DM, et al. Practice Advisory update summary: Patent foramen ovale and secondary stroke prevention. Neurology. 2020;94:876-885. doi: 10.1212/WNL.0000000000009443